NEW YORK, April 26 - Atlas Venture has raised $950 million from institutional investors to start a new capital fund that will invest in early-stage communications, information technology, and life science companies, the venture capital firm said Thursday.

The new fund, called Atlas Venture VI, will invest in both US and European early-stage companies, and will likely divide funding equally between the three business sectors, said a spokeswoman for Atlas Venture.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.